Overview

A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

This is a phase-1, single center, open-label, randomized, single-dose, 2-way crossover study. The objective of the study is to compare the pharmacokinetic properties after co-administration of Repaglinide 2mg and Metformin hydrochloride 500mg with administration of combination preparation of Repaglinide 2mg and Metformin hydrochloride 500mg in 50 healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Dalim BioTech Co., Ltd.

Treatments:

Metformin
Repaglinide